Neuroprotection in the adjunctive treatment of early POAG stages
In the article, authors have shown the possibility of the adjunctive treatment of POAG stages 1 and 2 by neuroprotectors of “direct and indirect” action. The data of studies carried on in the Saint-Petersburg Diagnostic Centre #7 from 2005 - to evaluate the efficacy of cytomedine and Ginkgo biloba preparation (EGb 761) - were used. Clinical monitoring of the patients under treatment was based both on objective estimation by instrumental methods: electrophysiology, morphometry, and vascular ones, and on subjective estimation of visual function preservation. Following results were obtained: on the background of adjunctive neuroprotective therapy an improvement of the visual analyzer functional status at theneuron level I, II and III, as well as an increased tolerance of the optic nerve to the increased IOP. Based on the performed study, following conclusions may be drawn: the neuroprotective therapy is a promising perspective of glaucomatous optic neuropathy treatment.